Exelixis | EXEL - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Akebia Therapeutics USD 160.86M 13.02M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Bayer EUR 32.27B 1.19B 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cytokinetics USD 181.43M 17.76M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Exelixis USD 361.93M 9.05M 2026-06
Genmab DKK 1.14B 38M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
MacroGenics USD 108.82M 12.88M 2026-06
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.76T 335.02B 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Xencor USD 81.86M 8.41M 2026-06